Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 4Neoplasms 3Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Sarcoma 1Prostate Cancer Metastatic 1Pancreatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1

Interventions

Doxorubicin 33pembrolizumab 16Gemcitabine 15eribulin 10Irinotecan 10olaratumab 9Trabectedin 9pazopanib 8Docetaxel 8Injections 7Cyclophosphamide 7Nivolumab 6Fluorouracil 6anlotinib 5Temozolomide 5Ipilimumab 5Ifosfamide 5Bevacizumab 5tazemetostat 4ridaforolimus 4Drug Therapy 4Cetuximab 4Carboplatin 4toripalimab 3surufatinib 3spartalizumab 3ganitumab 3entrectinib 3conatumumab 3belinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Sarcoma × LY3023414 × Clear all
NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Eli Lilly and Company

Phase 1 Terminated
94 enrolled 28 charts
BreastGastrointestinalSarcoma

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡